# US 2021/0196842 A1 · Site-specific radiofluorination of peptides with 8-[18f]-fluorooctanoic acid catalyzed by lipoic acid ligase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0196842 A1
- Document ID: US20210196842A1
- Status: Published application
- Kind: A1
- Application number: 15/777,558
- Filed: 2016-11-29
- Published: 2021-07-01
- Earliest claimed: 2015-11-30
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Christopher DRAKE; Henry VANBROCKLIN; Charles CRAIK; Natalia SEVILLANO
- Web page: https://patentgrep.com/patent/US20210196842A1

## CPC

- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- C12N 15/10: Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA C07H21/00; preparation of non-structural polynucleotides from microorganisms or with enzymes C12P19/34)
- G01N 33/534: with radioactive label
- C12N 9/1241: {Nucleotidyltransferases (2.7.7)}
- C12Y 207/07063: Lipoate--protein ligase (2.7.7.63)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Y: ENZYMES

## Abstract

New methodologies for site-specifically radiolabeling proteins with the PET isotope [1SF] are required to generate high quality radiotracers for imaging in both the preclinical and clinical settings. The enzymatic radiofluorination overcomes many of the limitations encountered to date with purely chemical approaches. The bacterial enzyme lipoic acid ligase was used to conjugate [18F]-fluorooctanoic acid to both a small peptide and a Fab antibody fragment. Labeling was site-specific and highly efficient under mild aqueous conditions using small amounts of peptide/protein (1-10 nmol). The labeled construct retained full epitope binding affinity and was stable in mouse serum. Using an optimized reaction scheme, mCi quantities of [18F]-Fab were generated, an amount sufficient for human imaging.

## Claims

### Claim 1

A method of conjugating a detectable label or therapeutic agent to a protein fusion between a targeting polypeptide and an acceptor polypeptide for a lipoic acid prosthesis comprising a domain recognized by a lipoic acid ligase and said detectable label or said therapeutic agent, said method comprising:
contacting said fusion with said prosthetic and said lipoic acid ligase under conditions such that said lipoic acid ligase transfers said prosthetic to said acceptor polypeptide, thereby conjugating said detectable label of therapeutic agent to said protein fusion .

### Claim 2 (depends on 1)

The method according to claim 1, wherein said prosthetic comprises a detectable label which is a radioisotope.

### Claim 3 (depends on 2)

The method according to claim 2, wherein said radioisotope is a positron emitting radioisotope.

### Claim 4 (depends on 3)

The method according to claim 3, wherein said radioisotope is 18F.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said acceptor polypeptide is at least about 95% homologous with the sequence GFEIDKVWYDLDA (SEQ. ID. NO: 2) .

### Claim 6 (depends on 1)

The method according to claim 1, wherein said lipoic acid ligase is of a sequence at least about 95% homologous with the sequence of SEQ. ID. NO: 1.

### Claim 7 (depends on 1)

The method according to claim 1, wherein said prosthetic is of a structure according to Formula I:
in which R1 is a detectable label selected from a radioisotope, a fluorophore or a mass spectrometric label, or R1 is a reactive functional group, a therapeutic agent, e.g., a toxin or, optionally, R1 is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, functionalized with said detectable moiety or said therapeutic moiety; the index n is an integer from 6-18.

### Claim 8 (depends on 7)

The method according to claim 7, wherein said prosthetic is:
F—(CH2)7—COOH.

### Claim 9 (depends on 1)

A protein conjugate formed by a method according to claim 1.

### Claim 10 (depends on 9)

The protein conjugate according to claim 9, in formulation with a pharmaceutically acceptable carrier.

### Claim 11 (depends on 9)

A method of acquiring a positron emission tomographic image, said method comprising:
(a) administering to a subject in need of obtaining a positron emission tomographic image a diagnostically useful amount of a protein conjugate according to claim 9; and
(b) acquiring said positron emission tomographic image of said subject following said administering.

### Claim 12 (depends on 1)

A kit for preparing a conjugate by a method according to claim 1, said kit comprising:
(a) a vessel containing said prosthetic;
(b) a vessel containing said lipoid acid ligase;
(c) a vessel containing said protein fusion; and, optionally one or more solvents, buffers, devices for administering said conjugate to a subject, and instructions for preparing said conjugate and/or instructions for using said conjugate to obtain a positron emission tomographic image of a subject in need thereof.
